Major League Baseball announced on January 9, 2026, that free agent outfielder Max Kepler has been suspended for 80 games after violating the league’s Joint Drug Prevention and Treatment Program. Kepler, who most recently played for the Philadelphia Phillies during the 2025 season, tested positive for a performance-enhancing substance prohibited under MLB’s drug policy.
Kepler entered free agency following the conclusion of the 2025 season. The 33-year-old German-born player had spent the bulk of his MLB career with the Minnesota Twins, establishing himself as a regular starting outfielder and noted for his defensive capabilities and left-handed power at the plate. He joined the Phillies before the 2025 campaign, contributing as part of their outfield rotation.
The 80-game suspension, effective immediately, will take place at the start of the 2026 regular season for any team that signs Kepler, significantly impacting his potential return to Major League action. Under the terms of MLB’s drug policy, a first-time performance-enhancing drug offense results in an 80-game ban.
Major League Baseball did not disclose the specific substance found during testing, adhering to its standard confidentiality policy regarding such matters. Kepler has not made a public statement addressing the suspension or providing context for the violation.
This disciplinary action may affect Kepler’s prospects in free agency, as teams will factor in both his on-field potential and the impact of the suspension when considering roster moves. The Philadelphia Phillies have not issued a comment regarding their former player’s suspension.
Kepler previously had no known history of violating MLB’s drug policy. His case marks the latest in a series of suspensions related to performance-enhancing substances, which MLB continues to monitor as part of its broader effort to ensure fairness and integrity in the sport.
Further details about Kepler’s future and any plans to appeal the decision or issue a formal statement have not been made public at this time.
